IP Library › Granted Patent US 11,311,479
Granted Patent B2
US 11,311,479 · App. 16/702,649 · Granted Apr 26, 2022

Nanoparticles comprising tacrolimus

Inventors: Wolfgang Beier (Munich, DE); Elke Horstkotte (Munich, DE)
Assignee: LEON-NANODRUGS GMBH
A61K9/006A61K9/5138A61K9/5146A61K9/5161A61K9/5192A61K31/436
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,311,479
App. No.
16/702,649
Granted
Apr 26, 2022
Kind
B2
Abstract

Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Claims (13)

1. A method for producing nanoparticles containing tacrolimus or a salt thereof, the method comprising steps of:

a) providing a solution of tacrolimus or a salt thereof in an organic solvent;

b) providing a liquid non-solvent for the tacrolimus or the salt thereof;

c) precipitating nanoparticles containing the tacrolimus or the salt thereof by colliding a stream of the organic solvent from step a) with a stream of the non-solvent from step b); and

d) isolating the nanoparticles, wherein the nanoparticles have a size of from 10 nm to 400 nm, and a polydispersity index of less than or equal to about 0.4.

2. The method according to claim 1 , wherein the solvent further comprises ethanol, methanol, acetone, and/or tetrahydrofuran.

3. The method according to claim 1 , wherein the non-solvent comprises water.

4. The method according to claim 1 , wherein the solvent and/or the non-solvent further comprises at least one stabilizing agent including polyvinyl pyrrolidone, vinylpyrrolidone-/vinylacetate-copolymer, polyethylenglycol and/or a cellulose derivative.

5. The method according to claim 1 , wherein the non-solvent further comprises a non-ionic surfactant and/or an ionic surfactant.

6. The method according to claim 1 , wherein the stream of the organic solvent from step a) and the stream of the non-solvent from step b) are collided with a velocity of about 1 m/sec to about 100 m/sec.

7. The method according to claim 1 , wherein the stream of the organic solvent from step a) and the stream of the non-solvent from step b) are collided with a velocity of about 50 m/sec.

8. The method according to claim 1 , wherein a volume ratio of the solvent and the non-solvent is between about 1:1 and about 1:5.

9. The method according to claim 4 , wherein the cellulose derivative is selected from hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose acetate succinate (HPMCAS), hydroxypropyl cellulose (HPC), and/or carboxymethyl cellulose (CMC).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2023
From: LEON-NANODRUGS GMBH
To: NUCLEUS MEDICAL GMBH
Reel/Frame 064764/0347 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ENTITY ON DOCUMENT PREVIOUSLY RECORDED AT REEL: 051357 FRAME: 0004. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 10, 2022
From: BEIER, WOLFGANG; HORSTKOTTE, ELKE
To: LEON-NANODRUGS GMBH
Reel/Frame 058652/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2019
From: BEIER, WOLFGANG; HORSTKOTTE, ELKE
To: LEON-NANODRUGS GMBH
Reel/Frame 051357/0004 →
Priority Claims (1)
DE 10 2018 130 848.5 · Dec 4, 2018 · national
Continuity (1)
Related Publication 20200170934A1 · Jun 4, 2020